{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3768, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a hub-and-spoke diagram where a central image of a fuel cell stack connects to five distinct strategic pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/3", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "c41e0b30-decf-4e56-9bcd-adea30c02d28", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Humble Origins", "beatSlug": "rags-to-riches-humble-origins", "evidence": "The presentation starts with an overview of Hyzon's current state, including their technology and market position.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "executive_summary", "function": "establish_context", "notes": "The slide uses a three-row structure to categorize business activities and a right-hand sidebar for key company metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/4", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "c41e0b30-decf-4e56-9bcd-adea30c02d28", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Humble Origins", "beatSlug": "rags-to-riches-humble-origins", "evidence": "The presentation starts with an overview of Hyzon's current state, including their technology and market position.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "kpi_overview", "function": "present_solution", "notes": "Includes technical specifications for three tiers of fuel cell trucks (Short, Medium, Long range).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/5", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 5, "beatId": "bfed1f80-b1fc-4e2b-bc76-e4f064d589d5", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Early Struggles", "beatSlug": "rags-to-riches-early-struggles", "evidence": "The presentation highlights Hyzon's business highlights and challenges in 2023.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "before_after", "function": "present_solution", "notes": "The slide uses a central product image to anchor the comparison between IP metrics on the left and performance metrics on the right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/6", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-6", "loopMatches": [ { "to": 6, "from": 6, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "a22dc57a-8910-4b79-8f40-29c46a78a6fc", "evidence": "The presentation uses a clear before-and-after comparison to showcase the advantages of Hyzon's technology.", "position": 0, "objective": "Illustrate the benefits of Hyzon's single-stack fuel cell technology compared to traditional approaches.", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.8, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 7, "from": 5, "beatId": "bfed1f80-b1fc-4e2b-bc76-e4f064d589d5", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Early Struggles", "beatSlug": "rags-to-riches-early-struggles", "evidence": "The presentation highlights Hyzon's business highlights and challenges in 2023.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "key_takeaways", "function": "summarize", "notes": "Uses a vertical timeline-style list to organize four key business pillars.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/7", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 5, "beatId": "bfed1f80-b1fc-4e2b-bc76-e4f064d589d5", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Early Struggles", "beatSlug": "rags-to-riches-early-struggles", "evidence": "The presentation highlights Hyzon's business highlights and challenges in 2023.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "sop_buildup", "function": "plan_implementation", "notes": "The slide uses a visual bridge between the two production milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/8", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 8, "beatId": "9642268a-37e0-4dbf-9a98-ab874560f621", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation showcases Hyzon's growth potential, including their scalable business model and significant market opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses a stacked bar chart for margin and a donut chart for cost breakdown, paired with a numbered list of strategic drivers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/9", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 8, "beatId": "9642268a-37e0-4dbf-9a98-ab874560f621", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation showcases Hyzon's growth potential, including their scalable business model and significant market opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "geographic_map", "function": "size_opportunity", "notes": "The slide highlights three specific programs: California HVIP, IRA ZE Port Equipment, and the US DoE Hydrogen Hub Program.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/10", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-10", "loopMatches": [ { "to": 10, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "de2592e5-835c-403a-a9d6-07c60c3c77ac", "evidence": "The presentation mentions the potential risks and consequences of not adopting Hyzon's technology.", "position": 1, "objective": "Highlight the potential consequences of not adopting Hyzon's technology, including missed opportunities and regulatory non-compliance.", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 14, "from": 8, "beatId": "9642268a-37e0-4dbf-9a98-ab874560f621", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation showcases Hyzon's growth potential, including their scalable business model and significant market opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a dual-section layout: a top table for the ramp-up model and a bottom section for current pipeline status with customer logos.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/11", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 8, "beatId": "9642268a-37e0-4dbf-9a98-ab874560f621", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation showcases Hyzon's growth potential, including their scalable business model and significant market opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a logo-grid to establish credibility through partner associations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/12", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 8, "beatId": "9642268a-37e0-4dbf-9a98-ab874560f621", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation showcases Hyzon's growth potential, including their scalable business model and significant market opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The chart uses a concentric semi-circle design to represent market layers, with a specific focus on HD trucking as the core.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/13", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 8, "beatId": "9642268a-37e0-4dbf-9a98-ab874560f621", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation showcases Hyzon's growth potential, including their scalable business model and significant market opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "timeline", "function": "summarize", "notes": "The slide uses icons to categorize milestones into Organization, Fuel cell, and Vehicle.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/14", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 8, "beatId": "9642268a-37e0-4dbf-9a98-ab874560f621", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Rising Success", "beatSlug": "rags-to-riches-rising-success", "evidence": "The presentation showcases Hyzon's growth potential, including their scalable business model and significant market opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a hub-and-spoke diagram with a central image of a fuel cell stack.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/15", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 15, "beatId": "bbf2d476-58be-4297-b01b-5d6be450b321", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "The presentation highlights Hyzon's achievements and financial progress, including declining cash burn and positive EBITDA.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/16", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 15, "beatId": "bbf2d476-58be-4297-b01b-5d6be450b321", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "The presentation highlights Hyzon's achievements and financial progress, including declining cash burn and positive EBITDA.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/17", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 15, "beatId": "bbf2d476-58be-4297-b01b-5d6be450b321", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "The presentation highlights Hyzon's achievements and financial progress, including declining cash burn and positive EBITDA.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table provides a breakdown of adjustments including fair value changes, stock-based compensation, and one-time charges.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/18", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 15, "beatId": "bbf2d476-58be-4297-b01b-5d6be450b321", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "The presentation highlights Hyzon's achievements and financial progress, including declining cash burn and positive EBITDA.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "kpi_overview", "function": "summarize", "notes": "Includes footnotes regarding SEC settlement payments and cash position dates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/19", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 15, "beatId": "bbf2d476-58be-4297-b01b-5d6be450b321", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "The presentation highlights Hyzon's achievements and financial progress, including declining cash burn and positive EBITDA.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-aacf-726c-b272-1a549c52e30e", "docSlug": "bd50c9551c145d8214476d5e1c001d59", "documentTitle": "Hyzon | Investor Conference Presentation Deck | 20 slides", "authorId": "hyzon", "authorName": "Hyzon", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "before_after", "function": "analyze_data", "notes": "The slide uses a before-after donut chart comparison and a supporting table to detail the share movement.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-aacf-726c-b272-1a549c52e30e/20", "deckHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e", "deckAnchorHref": "/decks/019de076-aacf-726c-b272-1a549c52e30e#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 20, "beatId": "3519f97d-68a0-403a-9000-025cad6fcc67", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "The presentation concludes with Hyzon's future outlook and potential for growth and profitability.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Includes company logo, tagline, mission statement, date, and ticker symbol.", "imagePath": "https://imgproxy.kitesheet.com/Er4DW2rsoYzp85L9vo5jsE-rTRR0lU5L3R6C_GIVWAs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmOTU5MjcyMWFkYjEwMmFlYmEzZDY0MGUwNjhjYS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/1", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "4664fc32-4b95-4b88-9160-8ea59df82e78", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Slides 1-5 provide an overview of Immix Biopharma and the N-GENIUS Platform", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/ljR7xGj_KZWOU9GJbSf-teWN9_0Lelp7xMM69ekrwEg/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmOTU5MjcyMWFkYjEwMmFlYmEzZDY0MGUwNjhjYS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/hqMF1rftcB5xdO31AWoE9XGeeQ_LL_ONHaQtWUTnhnI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmOTU5MjcyMWFkYjEwMmFlYmEzZDY0MGUwNjhjYS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/EcxvLLrHFKQJq6dTwxtqKzRy4IVLeMxhWb2zC6VubqE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmOTU5MjcyMWFkYjEwMmFlYmEzZDY0MGUwNjhjYS9wMDAxLnBuZw" }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/2", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "4664fc32-4b95-4b88-9160-8ea59df82e78", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Slides 1-5 provide an overview of Immix Biopharma and the N-GENIUS Platform", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a numbered list format to present key company milestones and clinical data points.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/3", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "4664fc32-4b95-4b88-9160-8ea59df82e78", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Slides 1-5 provide an overview of Immix Biopharma and the N-GENIUS Platform", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "team_bio", "function": "other", "notes": "The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/4", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "4664fc32-4b95-4b88-9160-8ea59df82e78", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Slides 1-5 provide an overview of Immix Biopharma and the N-GENIUS Platform", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "other", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/5", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "4664fc32-4b95-4b88-9160-8ea59df82e78", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "Slides 1-5 provide an overview of Immix Biopharma and the N-GENIUS Platform", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "other", "function": "present_solution", "notes": "Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/6", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a hub-and-spoke diagram to centralize the problem of neurotoxicity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/7", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-7", "loopMatches": [ { "to": 8, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "121a95bf-b39f-4f50-b7d1-f7d3a325321e", "evidence": "Slides 7-8 highlight the limitations of current CAR-T therapies", "position": 0, "objective": "What is the cost of inaction for current CAR-T therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 7, "beatId": "c962cea8-102a-4bc7-8d0f-aa1442fcfcf5", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "Slides 7-8 highlight the problem of neurotoxicity in CAR-T therapies and its impact on AL Amyloidosis and multiple myeloma", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "key_takeaways", "function": "present_solution", "notes": "Includes flow cytometry plots and bar charts showing efficacy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/8", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-8", "loopMatches": [ { "to": 8, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "121a95bf-b39f-4f50-b7d1-f7d3a325321e", "evidence": "Slides 7-8 highlight the limitations of current CAR-T therapies", "position": 0, "objective": "What is the cost of inaction for current CAR-T therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 7, "beatId": "c962cea8-102a-4bc7-8d0f-aa1442fcfcf5", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "Slides 7-8 highlight the problem of neurotoxicity in CAR-T therapies and its impact on AL Amyloidosis and multiple myeloma", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide highlights the structural modification of the binding domain in NXC-201 compared to the reference Abecma.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/9", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "other", "function": "present_solution", "notes": "The slide uses a schematic diagram to map specific protein domains to their functional benefits.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/10", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "other", "function": "present_solution", "notes": "Includes citations from Nature Signal Transduction and Targeted Therapy and Nature Medicine.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/11", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a combination of bar charts for preclinical data and a summary table for clinical outcomes to demonstrate the superiority of NXC-201.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/12", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "key_takeaways", "function": "present_solution", "notes": "The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/13", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "key_takeaways", "function": "summarize", "notes": "The diagram highlights four key clinical outcomes: no Parkinson's-like symptoms, short hospital stays, broad hospital access, and no deaths in clinical trials.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/14", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/15", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a biological illustration to highlight structural differences in binding domains and intracellular signaling components.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/16", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "other", "function": "present_solution", "notes": "Includes comparative data points for CAR-T characteristics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/17", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "other", "function": "analyze_data", "notes": "The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/18", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 9, "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a process flow diagram to connect cellular pathology to clinical manifestations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/19", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The diagram shows a summation of ~29,712 (prevalence) and ~3,040 (derived from incidence) to reach ~32,752 eligible patients.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/20", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/21", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/22", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-22", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/23", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/24", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/25", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes a footnote citing FDA approval precedents for similar single-arm studies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/26", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-26", "loopMatches": [ { "to": 29, "from": 26, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645", "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts", "position": 1, "objective": "Why is now the right time for NXC-201?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a before-and-after visual comparison to illustrate market expansion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/27", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-27", "loopMatches": [ { "to": 29, "from": 26, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645", "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts", "position": 1, "objective": "Why is now the right time for NXC-201?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "comparison_table", "function": "compare_peers", "notes": "Includes detailed source citations in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/28", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-28", "loopMatches": [ { "to": 29, "from": 26, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645", "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts", "position": 1, "objective": "Why is now the right time for NXC-201?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a two-column layout to separate milestones for two distinct drug programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/29", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-29", "loopMatches": [ { "to": 29, "from": 26, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645", "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts", "position": 1, "objective": "Why is now the right time for NXC-201?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "roadmap", "function": "present_solution", "notes": "The slide uses a standard pharmaceutical pipeline table format to communicate clinical progress and regulatory milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/30", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-30", "loopMatches": [ { "to": 32, "from": 30, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "97496501-8d4d-4cba-92cc-0cef806b4d26", "evidence": "Slides 30-32 discuss the market opportunity for NXC-201", "position": 2, "objective": "What is the potential for NXC-201 in large markets?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/31", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-31", "loopMatches": [ { "to": 32, "from": 30, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "97496501-8d4d-4cba-92cc-0cef806b4d26", "evidence": "Slides 30-32 discuss the market opportunity for NXC-201", "position": 2, "objective": "What is the potential for NXC-201 in large markets?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a wave-like visual to represent market segments and their associated dollar values.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/32", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-32", "loopMatches": [ { "to": 32, "from": 30, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "97496501-8d4d-4cba-92cc-0cef806b4d26", "evidence": "Slides 30-32 discuss the market opportunity for NXC-201", "position": 2, "objective": "What is the potential for NXC-201 in large markets?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/33", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-33", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/34", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-34", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "comparison_table", "function": "compare_peers", "notes": "The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/35", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-35", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a two-column layout to contrast clinical outcomes for two different indications, followed by a row of competitor product logos and financial metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/36", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-36", "loopMatches": [], "arcBeatMatches": [ { "to": 36, "from": 19, "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 19-36 provide clinical data and results for NXC-201", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "other", "function": "analyze_data", "notes": "The chart illustrates deepening responses in patients treated with NXC-201 over time.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/37", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-37", "loopMatches": [], "arcBeatMatches": [ { "to": 64, "from": 37, "beatId": "55323ebe-ee93-4119-be72-15ce337e4875", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "other", "function": "present_solution", "notes": "The slide uses a combination of biological pathway diagrams, pharmacokinetic data, and efficacy metrics to demonstrate the therapeutic advantage of IMX-110.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/38", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-38", "loopMatches": [], "arcBeatMatches": [ { "to": 64, "from": 37, "beatId": "55323ebe-ee93-4119-be72-15ce337e4875", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide uses a numbered list format to present clinical milestones and market opportunities.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/39", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-39", "loopMatches": [], "arcBeatMatches": [ { "to": 64, "from": 37, "beatId": "55323ebe-ee93-4119-be72-15ce337e4875", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/40", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-40", "loopMatches": [], "arcBeatMatches": [ { "to": 64, "from": 37, "beatId": "55323ebe-ee93-4119-be72-15ce337e4875", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Uses icon-based visualization to represent market expansion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/41", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-41", "loopMatches": [], "arcBeatMatches": [ { "to": 64, "from": 37, "beatId": "55323ebe-ee93-4119-be72-15ce337e4875", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd", "docSlug": "9e6f9592721adb102aeba3d640e068ca", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "other", "function": "present_solution", "notes": "The slide uses a process flow diagram to illustrate dose escalation steps.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/42", "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd", "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-42", "loopMatches": [], "arcBeatMatches": [ { "to": 64, "from": 37, "beatId": "55323ebe-ee93-4119-be72-15ce337e4875", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }